Aridis Pharmaceuticals, Inc.

107 articles with Aridis Pharmaceuticals, Inc.

• Aridis Pharmaceuticals Announces $2.28 Million Registered Direct Offering of Common Stock

  3/14/2023

  Aridis Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering.

• Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

  1/25/2023

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus).

• New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update

  1/17/2023

  Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in Key Opinion Leader (KOL) event focusing on the anti-infective treatment landscape in cystic fibrosis (CF) and the Company’s Phase 2a trial of AR-501 in CF patients.

• Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25

  12/28/2022

  Aridis Pharmaceuticals, Inc. will host a conference call and audio-only webcast on Wednesday, January 25, at 4:15 p.m. ET to provide a business and pipeline update, including a discussion of topline data from the Company’s Phase 3 study of AR-301 in adjunctive treatment of S. aureus ventilator associated pneumonia.

• Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

  12/12/2022

  Aridis Pharmaceuticals, Inc. today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis (CF) patients.

• (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation

  12/12/2022

  Aridis Pharmaceuticals, Inc., a biopharmaceutical company announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development of AR-501, an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in cystic fibrosis patients.

• Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical

  12/5/2022

  Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, signed an exclusive term sheet to secure international development and global commercial rights upon licensure for the pan-Ebola and pan-Marburg monoclonal antibody (mAbs) programs from Mapp Biopharmaceutical, Inc.

• Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

  11/30/2022

  Aridis Pharmaceuticals, Inc. today announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of AR-501 in cystic fibrosis (CF) patients.

• Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

  11/22/2022

  Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in H.C. Wainwright & Co.’s 2022 KOL Series (Part 8) on Tuesday, November 29, at 11 a.m. EST.

• Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update

  11/21/2022

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022.

• Aridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority Study

  10/4/2022

  Aridis Pharmaceuticals, Inc. announced that patient enrollment is closed in the AR-301 Phase 3 clinical study.

• Aridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock

  9/27/2022

  Aridis Pharmaceuticals, Inc. today announced that due to adverse market conditions, it has withdrawn its proposed public offering of shares of its common stock.

• Aridis Pharmaceuticals Announces Proposed Public Offering of Common Stock - September 26, 2022

  9/26/2022

  Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that it intends to offer its common stock in a public offering.

• Aridis Pharmaceuticals Announces Second Quarter 2022 Financial Results and Business Update

  8/16/2022

  Aridis Pharmaceuticals, Inc. today reported financial and corporate results for its second quarter ended June 30, 2022. 

• Aridis' Pan-Coronavirus, Inhaled Monoclonal Antibody Cocktail AR-701 Is Protective in Non-Human Primates

  8/10/2022

  Aridis Pharmaceuticals, Inc. announced today that inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected rhesus macaques, and protected their lungs from disease.

• Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7

  6/3/2022

  Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that Vu Truong , Ph.D., Chief Executive Officer of Aridis Pharmaceuticals, will participate in a virtual fireside chat presented by Maxim Group LLC and hosted by M-Vest on June 7 at 11 a.m. ET.

• Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update

  5/16/2022

  Aridis Pharmaceuticals, Inc. reported financial and corporate results for its first quarter ended March 31, 2022.

• Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update

  3/31/2022

  Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, reported financial and corporate results for its fourth quarter and year ended December 31, 2021.

• Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

  2/17/2022

  Aridis Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, announced that both of its fully human monoclonal antibodies in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant.

• Aridis Pharmaceuticals Receives Funding to Evaluate Inhaled Monoclonal Antibodies to Block Influenza and SARS-CoV-2 Transmission

  1/27/2022

  Funding from the Bill & Melinda Gates Foundation will support the development of Aridis' inhaled formulation technology to deliver cost-effective monoclonal antibodies against influenza and COVID-19.